Patienter, som blev vurderet af investigator til at have et klinisk respons i uge 10 blev randomiseret og fik 5 mg/ kg infliximab enten hver 8. eller hver 12. uge som et vedligeholdelsesbehandlingsprogram.
Patients assessed by the investigator to be in clinical response at week 10 were randomized and received 5 mg/ kg infliximab at either q8 weeks or q12 weeks as a maintenance treatment regimen.